Milestone Pharmaceuticals Inc (MIST)

$1.38 +0.07 (5.34%)
Market Cap 162.38M
Revenue (ttm) 1.55M
Net Income (ttm) -63.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,068.39%
Debt to Equity Ratio 0.00
Volume 2,088,200
Avg Vol 1,967,628
Day's Range N/A - N/A
Shares Out 117.67M
Stochastic %K 95%
Beta 0.69
Analysts Strong Sell
Price Target $6.60

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a...

Industry: Biotechnology
Sector: Healthcare
Phone: 514 336 0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
gc358
gc358 Apr. 4 at 11:29 PM
$MIST Stopped in to this blog on a tip. Who are the main DD posters that I can catch up on MIST? TIA.
0 · Reply
JuggernautRaider
JuggernautRaider Apr. 4 at 8:25 PM
$MIST congrats to those who caught shares at $1.01. I almost pulled the trigger on my first 10K. Also long $TNXP $NUVB and $KALV - recently undervalued FDA launches with more to come 🚀
3 · Reply
KilroyPicks
KilroyPicks Apr. 3 at 8:36 PM
$MIST - the China phase 3 trail has completed once the approval (expected in Q3) is awarded MIST will receive $107.5 Million from Everest Pharmaceuticals plus tiered royalty payments net sales.
2 · Reply
KilroyPicks
KilroyPicks Apr. 3 at 8:30 PM
$MIST why I believe that MIST will be a buyout target once they get the Afib FDA approval. Over $300 Billion in patent protected revenue will be lost by the big pharma to generics producing companies this year. Big pharma will be aggressively approaching small pharmas that have long patent horizons. MIST current CARDAMYST patent protection expires in July of 2042. This will give any major pharma a minimum of 15 years of additional protected revenue. With Europe and China coming online in the next 6 to 12 months this will expand MIST customer potential by 5x and that is just with PSVT . Once Europe and China are approved this will transform Milestone to the global leader of self administered cardiovascular care. This will be a huge carrot for any major pharma.
1 · Reply
KilroyPicks
KilroyPicks Apr. 3 at 8:11 PM
$MIST - Why I believe that MIST will get a buyout offer after the Afib study is approved. Over $300 Billion in patent protected pharmacuticals
0 · Reply
KilroyPicks
KilroyPicks Apr. 3 at 7:45 PM
$MIST - on March 20th, Trails Edge Capital Partners bout 5,333,333 shares of price of $1.36 per share. https://www.gurufocus.com/news/8766230/trails-edge-capital-partners-lp-acquires-5333333-shares-in-milestone-pharmaceuticals-inc?mobile=true
1 · Reply
Vincybull
Vincybull Apr. 3 at 5:56 PM
$MIST I hope it will be purchased in November/December 2027.
1 · Reply
doledav
doledav Apr. 3 at 2:58 PM
$MIST I believe these warrants have to be exercised if the share price hits 3.75, you can almost bet it will be done before July when they expire. There is a chance they expire worthless but I wouldn’t be shocked to see this hit the automatic exercise price.
2 · Reply
Starlord10
Starlord10 Apr. 3 at 1:41 PM
$MIST Gap at $1.64. Rising scripts. New country adoption. CVS and Optum. Good momentum and PR opportunities forthcoming. Mind the gap.
1 · Reply
Starlord10
Starlord10 Apr. 3 at 1:35 PM
$MIST
0 · Reply
Latest News on MIST
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2026, 8:00 AM EDT - 3 days ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

Mar 31, 2026, 8:00 AM EDT - 5 days ago

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Mar 20, 2026, 6:32 PM EDT - 15 days ago

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Why Milestone Pharma Stock Is Taking A Dive Today

Mar 20, 2026, 11:40 AM EDT - 15 days ago

Why Milestone Pharma Stock Is Taking A Dive Today

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

Mar 20, 2026, 7:12 AM EDT - 16 days ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Mar 20, 2026, 2:23 AM EDT - 16 days ago

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

Mar 16, 2026, 8:13 AM EDT - 20 days ago

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

Mar 12, 2026, 8:00 AM EDT - 24 days ago

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 8:00 AM EST - 5 weeks ago

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

Feb 10, 2026, 8:00 AM EST - 7 weeks ago

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Jan 26, 2026, 8:00 AM EST - 2 months ago

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

Jan 15, 2026, 9:45 AM EST - 2 months ago

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Jan 6, 2026, 8:00 AM EST - 3 months ago

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript

Dec 15, 2025, 11:59 AM EST - 3 months ago

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Dec 12, 2025, 8:00 PM EST - 4 months ago

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Nov 12, 2025, 7:01 AM EST - 5 months ago

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Nov 3, 2025, 8:00 AM EST - 5 months ago

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Oct 9, 2025, 8:00 AM EDT - 6 months ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 19, 2025, 8:00 AM EDT - 8 months ago

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Aug 12, 2025, 7:05 AM EDT - 8 months ago

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Jul 18, 2025, 2:16 PM EDT - 9 months ago

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Jul 11, 2025, 2:37 PM EDT - 9 months ago

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Jul 11, 2025, 9:30 AM EDT - 9 months ago

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:01 AM EDT - 9 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Jul 11, 2025, 6:00 AM EDT - 9 months ago

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Jul 7, 2025, 10:01 AM EDT - 9 months ago

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Jun 16, 2025, 8:00 AM EDT - 10 months ago

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 11 months ago

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

May 14, 2025, 7:04 AM EDT - 11 months ago

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Stock Picks From Seeking Alpha's March 2025 New Analysts

Apr 4, 2025, 2:30 PM EDT - 1 year ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI ARGX CCL CEPU CF CROX CUK

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

Mar 28, 2025, 10:24 AM EDT - 1 year ago

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Mar 28, 2025, 7:06 AM EDT - 1 year ago

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 1 year ago

FDA Issues Complete Response Letter for Etripamil for PSVT

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Mar 21, 2025, 3:18 PM EDT - 1 year ago

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Mar 13, 2025, 7:08 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Feb 19, 2025, 8:00 AM EST - 1 year ago

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Jan 28, 2025, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Nov 12, 2024, 9:03 AM EST - 1 year ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Aug 8, 2024, 4:17 PM EDT - 1 year ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 31, 2024, 8:00 AM EDT - 2 years ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 29, 2024, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

May 13, 2024, 7:15 AM EDT - 2 years ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 8, 2024, 11:36 AM EDT - 2 years ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

gc358
gc358 Apr. 4 at 11:29 PM
$MIST Stopped in to this blog on a tip. Who are the main DD posters that I can catch up on MIST? TIA.
0 · Reply
JuggernautRaider
JuggernautRaider Apr. 4 at 8:25 PM
$MIST congrats to those who caught shares at $1.01. I almost pulled the trigger on my first 10K. Also long $TNXP $NUVB and $KALV - recently undervalued FDA launches with more to come 🚀
3 · Reply
KilroyPicks
KilroyPicks Apr. 3 at 8:36 PM
$MIST - the China phase 3 trail has completed once the approval (expected in Q3) is awarded MIST will receive $107.5 Million from Everest Pharmaceuticals plus tiered royalty payments net sales.
2 · Reply
KilroyPicks
KilroyPicks Apr. 3 at 8:30 PM
$MIST why I believe that MIST will be a buyout target once they get the Afib FDA approval. Over $300 Billion in patent protected revenue will be lost by the big pharma to generics producing companies this year. Big pharma will be aggressively approaching small pharmas that have long patent horizons. MIST current CARDAMYST patent protection expires in July of 2042. This will give any major pharma a minimum of 15 years of additional protected revenue. With Europe and China coming online in the next 6 to 12 months this will expand MIST customer potential by 5x and that is just with PSVT . Once Europe and China are approved this will transform Milestone to the global leader of self administered cardiovascular care. This will be a huge carrot for any major pharma.
1 · Reply
KilroyPicks
KilroyPicks Apr. 3 at 8:11 PM
$MIST - Why I believe that MIST will get a buyout offer after the Afib study is approved. Over $300 Billion in patent protected pharmacuticals
0 · Reply
KilroyPicks
KilroyPicks Apr. 3 at 7:45 PM
$MIST - on March 20th, Trails Edge Capital Partners bout 5,333,333 shares of price of $1.36 per share. https://www.gurufocus.com/news/8766230/trails-edge-capital-partners-lp-acquires-5333333-shares-in-milestone-pharmaceuticals-inc?mobile=true
1 · Reply
Vincybull
Vincybull Apr. 3 at 5:56 PM
$MIST I hope it will be purchased in November/December 2027.
1 · Reply
doledav
doledav Apr. 3 at 2:58 PM
$MIST I believe these warrants have to be exercised if the share price hits 3.75, you can almost bet it will be done before July when they expire. There is a chance they expire worthless but I wouldn’t be shocked to see this hit the automatic exercise price.
2 · Reply
Starlord10
Starlord10 Apr. 3 at 1:41 PM
$MIST Gap at $1.64. Rising scripts. New country adoption. CVS and Optum. Good momentum and PR opportunities forthcoming. Mind the gap.
1 · Reply
Starlord10
Starlord10 Apr. 3 at 1:35 PM
$MIST
0 · Reply
wschi7767
wschi7767 Apr. 3 at 2:58 AM
$MIST this is all bs fake gains… get out while u still can
6 · Reply
vmoe001
vmoe001 Apr. 2 at 11:19 PM
$MIST i believe they are funded through late 2027? Bueller?
1 · Reply
Ga_glovo
Ga_glovo Apr. 2 at 10:50 PM
$MIST Possible incoming events/announcements scenario – this will propel the stock towards USD 6-7 till end of 2027. 1. Changing tone in 1Q26 – launch exceeds expectations as well as negotiation dynamic and feedbacks from payers, doctors and patients 2. Rising scripts, doctors and patients adoptions 3. 2Q26 will show material sales – scripts are not blocked as in 1Q26 4. CVS and Optum will approve 5. China approvals pop 6. 3Q26 shows further rise in scripts 7. In 1Q27 they announce P3 afib start 8. EMA approval pop 9. Scripts rise further as commercial coverage is fully obtained 10. Medicare obtained 11. They guide cash brake-even till 4Q27 12. BO appears all this requires patience and around 18 months from now
2 · Reply
Diverstj981
Diverstj981 Apr. 2 at 10:48 PM
$MIST Anyone else feel like dancing after seeing this AH continuation? I might be white as fahk but I'll do my best. 😆🕺🕺
0 · Reply
lookingaroundhere
lookingaroundhere Apr. 2 at 10:36 PM
$MIST Finally.
0 · Reply
Ga_glovo
Ga_glovo Apr. 2 at 10:19 PM
$MIST +6% post market 😅
0 · Reply
Juggsy
Juggsy Apr. 2 at 10:15 PM
$MIST be poppin! last time it did this for me after hours it went up 50% next day. ready
0 · Reply
kirk1985
kirk1985 Apr. 2 at 10:04 PM
$WVE $LPCN $AVXL $ADMA $MIST
0 · Reply
CCC501
CCC501 Apr. 2 at 9:54 PM
$MIST Back to break even. Never contemplated selling.
1 · Reply
Bennyman369
Bennyman369 Apr. 2 at 9:21 PM
$MIST $NIXX $CXAI 2026 multi baggers!! 💪🌊🏄‍♂️
0 · Reply
JanetBSmellin
JanetBSmellin Apr. 2 at 8:18 PM
$MIST Yes!!!!! My negativity worked! 🤡👍🏼 Got so mad I bought more at $1.01!
2 · Reply
Ga_glovo
Ga_glovo Apr. 2 at 8:11 PM
$MIST 1.4 post market - we go towards full recovery next week - retail lost money on this and contributed self-destruction only due to luck of patience and complete misunderstanding of commercialization timelines...we had virtually no single bad news from MIST since FDA approval, only a line of positive announcements.
1 · Reply